Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Salami, Simpa Samuel

University Of Michigan At Ann Arbor
United States

Defining the Biological Arc of Grade Group 1 Prostate Cancer 5R37CA283857-03 Guillermo Marquez, Ph.D.
Salipante, Stephen J

University Of Washington
United States

Efficient, cost-effective, and ultrasensitive sequencing of somatic mutations and methylation 1R33CA302385-01 Nicholas Hodges, Ph.D.
Salkowski, Lonie

University Of Wisconsin-Madison
United States

Defining and Optimizing Critical Interpretation Skills in Screening Mammography to Improve Cancer Detection 5R37CA262110-04 Guillermo Marquez, Ph.D.
Salman, Emad

Florida Assn Of Pediatric Tumor Prog
United States

The Florida Pediatric NCORP: NCI Community Oncology Research Program. 3UG1CA189973-11S1 Vanessa A. White, M.P.H.
Salman, Emad

Florida Assn Of Pediatric Tumor Prog
United States

The Florida Pediatric NCORP: NCI Community Oncology Research Program. 3UG1CA189973-11S1 Vanessa A. White, M.P.H.
Salvemini, Daniela

Saint Louis University
United States

Fingolimod and Ozanimod for the treatment and prevention of chemobrain 5R01CA261979-04 Rachel Altshuler, Ph.D.
Salvemini, Daniela

Saint Louis University
United States

Fingolimod and Ozanimod for the treatment and prevention of chemobrain 5R01CA261979-04 Rachel Altshuler, Ph.D.
Sanchez, Eduardo Vilar

University Of Tx Md Anderson Can Ctr
United States

Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome 5R01CA260761-04 Asad Umar, D.V.M., Ph.D.
Sanchez, Eduardo Vilar

University Of Tx Md Anderson Can Ctr
United States

iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium 2UG1CA242609-07 Donald Johnsey
Sanchez, Eduardo Vilar

University Of Tx Md Anderson Can Ctr
United States

Cancer Immune-Interception for Lynch Syndrome 5R01CA257375-05 Asad Umar, D.V.M., Ph.D.
Sanda, Martin G

Emory University
United States

Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern 5U01CA113913-18 Indu Kohaar, Ph.D., M.Phil., M.Sc.
Sanda, Martin G

Emory University
United States

Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern 5U01CA113913-18 Indu Kohaar, Ph.D., M.Phil., M.Sc.
Sands, Stephen Alan

Sloan-Kettering Inst Can Research
United States

Prospective international phase-III study to improve neurocognitive outcomes in young children with low-risk medulloblastoma (YCMB-LR) 5R01CA283045-02 Marjorie Perloff, M.D.
Sands, Stephen Alan

Sloan-Kettering Inst Can Research
United States

Prospective international phase-III study to improve neurocognitive outcomes in young children with low-risk medulloblastoma (YCMB-LR) 5R01CA283045-02 Marjorie Perloff, M.D.
Sands, Stephen Alan

Sloan-Kettering Inst Can Research
United States

Prospective international phase-III study to improve neurocognitive outcomes in young children with low-risk medulloblastoma (YCMB-LR) 5R01CA283045-02 Marjorie Perloff, M.D.